Clinical trial of carbocisteine tablets combined with salbutamol aerosol in the treatment of patients with chronic obstructive pulmonary disease
10.13699/j.cnki.1001-6821.2024.02.001
- VernacularTitle:羧甲司坦片联合沙丁胺醇气雾剂治疗慢性阻塞性肺疾病患者的临床研究
- Author:
Jing LI
1
;
Kun WANG
Author Information
1. 青岛市市立医院西院区、青岛市老年病医院急诊科,山东青岛 266300
- Keywords:
salbutamol aerosol;
carbocisteine tablet;
chronic obstructive pulmonary disease;
oxidative stress response
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(2):155-159
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical efficacy of carbocisteine tablets combined with salbutamol aerosol in the treatment of chronic obstructive pulmonary disease(COPD),and its effect on lung function and oxidative stress indexes.Methods COPD patients were divided into treatment group and control group.The control group was treated with salbutamol aerosol,and the treatment group was treated with carbocisteine tablets on the basis of the control group,0.5 g each time,3 times a day for 3 months.The pulmonary function,oxidative stress index,COPD self-assessment test(CAT)and serum inflammatory factor levels were compared between the two groups.Results After treatment,the forced expiratory volume in one second/forced vital capacity(FEV1/FVC)of the treatment group and the control group were(83.26±3.88)％and(75.12±3.87)％;forced vital capacity(FVC)were(3.67±0.31)and(3.11±0.22)L;forced expiratory volume in one second(FEV1)were(1.65±0.17)and(1.43±0.11)L·s-1;total antioxidant capacity(T-AOC)were(36.81±3.09)and(23.25±2.10)U·mL-1;glutathione peroxidase(GPX)were(73.49±3.45)and(53.13±3.55)nmol·L-1;malondialdehyde(MDA)were(12.74±1.14)and(10.09±1.10)nmol·mL-1;superoxide dismutase(SOD)levels were(328.30±16.96)and(462.44±17.73)U·mL-1;the subjective scores of CAT were 11.04±2.00 and 18.03±3.23;the motor index scores were 4.16±1.80 and 6.66±1.76;the serum interleukin-17(IL-17)levels were(29.39±2.38)and(40.90±2.80)pg·mL-1;tumor necrosis factor-α(TNF-α)were(31.96±2.04)and(40.04±2.57)pg·mL-1;the high-mobilitygroup box 1(HMGB1)levels were(41.50±3.03)and(72.23±4.63)pg·mL-1;the differences were all statistically significant(all P＜0.05).The incidence of adverse drug reactions in the treatment group and the control group was 10.53％and 20.00％,respectively,and the difference was not statistically significant(P＞0.05).Conclusion The combination of carbocisteine tablets and salbutamol aerosol in the clinical treatment of COPD can effectively improve the clinical efficacy,reduce inflammatory response,improve pulmonary function ventilation,and reduce oxidative stress.
